What is the official website of Wockhardt Ltd. ?

The official website of Wockhardt Ltd. is http://www.wockhardt.com.

What is Wockhardt Ltd.'s cybersecurity risk score?

Wockhardt Ltd. has an AI-generated cybersecurity risk score of 840 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has Wockhardt Ltd. experienced?

According to Rankiteo, Wockhardt Ltd. currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Wockhardt Ltd. been affected by any supply chain cyber incidents ?

According to Rankiteo, Wockhardt Ltd. has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Wockhardt Ltd. have SOC 2 Type 1 certification ?

According to Rankiteo, Wockhardt Ltd. is not certified under SOC 2 Type 1.

Does Wockhardt Ltd. have SOC 2 Type 2 certification ?

According to Rankiteo, Wockhardt Ltd. does not hold a SOC 2 Type 2 certification.

Does Wockhardt Ltd. comply with GDPR ?

According to Rankiteo, Wockhardt Ltd. is not listed as GDPR compliant.

Does Wockhardt Ltd. have PCI DSS certification ?

According to Rankiteo, Wockhardt Ltd. does not currently maintain PCI DSS compliance.

Does Wockhardt Ltd. comply with HIPAA ?

According to Rankiteo, Wockhardt Ltd. is not compliant with HIPAA regulations.

Does Wockhardt Ltd. have ISO 27001 certification ?

According to Rankiteo,Wockhardt Ltd. is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Wockhardt Ltd. operate in ?

Wockhardt Ltd. operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Wockhardt Ltd. have ?

Wockhardt Ltd. employs approximately 7,259 people worldwide.

Does Wockhardt Ltd. own any subsidiaries ?

Wockhardt Ltd. presently has no subsidiaries across any sectors.

How many LinkedIn followers does Wockhardt Ltd. have ?

Wockhardt Ltd.'s official LinkedIn profile has approximately followers.

What is the NAICS classification code for Wockhardt Ltd. ?

Wockhardt Ltd. is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Wockhardt Ltd. have a Crunchbase profile ?

Yes, Wockhardt Ltd. has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/wockhardt.

Does Wockhardt Ltd. have a LinkedIn profile ?

Yes, Wockhardt Ltd. maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/wockhardt.

How many cybersecurity incidents has Wockhardt Ltd. experienced ?

As of June 9, 2026, Rankiteo reports that Wockhardt Ltd. has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Wockhardt Ltd. have ?

Wockhardt Ltd. has an estimated 5,682 peer or competitor companies worldwide.

What types of cybersecurity incidents has Wockhardt Ltd. faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Wockhardt Ltd.

Boost Score +25 with badge (5 left)

840

/1000

Good

865

/1000

Very Good

Wockhardt Ltd. Vendor Cyber Rating & Cyber Score

wockhardt.com

cb in

Add Your Compliance Badge

Wockhardt is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Specialty Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 3000 Wockhardt Associates from 21 different nationalities globally. It has 3 research centers and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. Headquartered in Mumbai, India, Wockhardt has

Wockhardt Ltd. A.I CyberSecurity Scoring

Scoring History

Wockhardt Ltd.

Wockhardt Ltd. CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Wockhardt Ltd.

Breach

12/2025

WOC1764906951

Loading…

A.I.

Wockhardt Ltd. Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Wockhardt Ltd.

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Wockhardt Ltd. in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Wockhardt Ltd. in 2026.

Incident Types Wockhardt Ltd. vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Wockhardt Ltd. in 2026.

Incident History - Wockhardt Ltd. (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Wockhardt Ltd. Subsidiaries

Wockhardt Ltd.

Pharmaceutical Manufacturing

Website: http://www.wockhardt.com

Company Size: 7,259

Wockhardt USAPharmaceutical Manufacturing

Loading…

Wockhardt Ltd. Similar Companies

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Loading…

NEWS

Wockhardt Ltd. CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

September 12, 2025 07:00 AM

Wockhardt-Shukra Pharma deal: Pharma majors sign pan-India distribution pact - Details

Distribution Deal: According to a PTI report, Shukra Pharma has entered into a pan-India distribution deal with global pharmaceutical and...

Read Article

September 10, 2025 07:00 AM

'Some data' affected by cybersecurity incident, says Jaguar Land Rover

Jaguar Land Rover confirmed that "some data" was impacted in a recent cyberattack that disrupted production and sales.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-44541

SUMMARY

Fides is an open-source privacy engineering platform. From version 2.33.0 to before version 2.84.5, there is a DOM-based XSS vulnerability in fides.js via the fides_description override. This issue has been patched in version 2.84.5.

Published

Date2026-06-08

Updated

Date2026-06-08

RISK INFORMATION (Score: )

cvss4

Base Score: 7.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:N/SC:H/SI:H/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-49141

SUMMARY

WACRM prior to commit 73041bf contain an authorization bypass vulnerability in the automation engine that allows authenticated attackers to access and modify contacts belonging to other tenants by supplying an arbitrary caller-controlled contact_id in the POST request body without tenant ownership verification. Attackers can exploit the service-role client that bypasses row-level security to modify victim contact fields including name, email, and company across tenant boundaries using only a known contact UUID.

Published

Date2026-06-08

Updated

Date2026-06-08

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:L/I:H/A:N

cvss4

Base Score: 5.1

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:N/VI:N/VA:N/SC:L/SI:H/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.7

Exploitability

1.8

REFERENCES

CVE-2026-47345

SUMMARY

Namespace attributes are not encoded correctly during HTML serialization. This allows bypassing the cross-site scripting prevention mechanism of typo3/html-sanitizer before version 2.3.2.

Published

Date2026-06-08

Updated

Date2026-06-08

RISK INFORMATION (Score: )

cvss4

Base Score: 5.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:N/VI:N/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-47344

SUMMARY

When ALLOW_INSECURE_RAW_TEXT is enabled, whitespace-variant closing tags (e.g., </style\t>) are not recognized by the sanitizer but accepted by browsers as valid end tags, allowing subsequent content to escape sanitization. This allows bypassing the cross-site scripting prevention mechanism of typo3/html-sanitizer before version 2.3.2.

Published

Date2026-06-08

Updated

Date2026-06-08

RISK INFORMATION (Score: )

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:P/VC:N/VI:N/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-46484

SUMMARY

Headplane is a feature-complete Web UI for Headscale. Prior to versions 0.6.3 and 0.7.0-beta.3, Headplane was vulnerable to a path traversal / authorization bypass in the Headscale API client used by node and user rename operations. This issue has been patched in versions 0.6.3 and 0.7.0-beta.3.

Published

Date2026-06-08

Updated

Date2026-06-08

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…